SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin to launch additional products to strengthen its branded portfolio

19 Aug 2013 Evaluate

With an aim to strengthen its branded portfolio, Pharma major Lupin, would be launching additional products either from its pipeline or from strategic brand acquisitions that have been developed and filed with the USFDA.

The company's US revenues grew by 54% to Rs 3,683 crore during FY 2013, up from Rs 2,393 crore in FY 2012. Meanwhile, new launches contributed 42% of the US generics revenues.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

Lupin Share Price

2419.10 -30.70 (-1.25%)
30-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 2000.75
Dr. Reddys Labs. 1144.35
Cipla 1466.00
Lupin 2419.10
Zydus Lifesciences 1115.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: